Cantor Fitzgerald analyst Jennifer Kim keeps an Overweight rating on EyePoint Pharmaceuticals after EW Healthcare Partner’s disclosed a reduced stake of 10.4% following its recent selling of shares. The analyst believes the language in the filing supports the firm’s view that the recent selloff in EyePoint shares is not fundamental and presents an attractive buying opportunity ahead of the DAVIO 2 data in December. Cantor keeps an Overweight rating on the stock with a $31 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EYPT:
- EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- Biotech Alert: Searches spiking for these stocks today
- EyePoint management to meet with Mizuho
- EyePoint reports inducement grants under Nasdaq listing rule
- EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference